Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial

David R Mandel, Katy Eichas, Judith Holmes, David R Mandel, Katy Eichas, Judith Holmes

Abstract

Background: Lactic acid-producing bacteria (LAB) probiotics demonstrate immunomodulating and anti-inflammatory effects and the ability to lessen the symptoms of arthritis in both animals and humans. This randomized, double-blind, placebo-controlled, parallel-design, clinical pilot trial was conducted to evaluate the effects of the LAB probiotic preparation, Bacillus coagulans GBI-30, 6086, on symptoms and measures of functional capacity in patients with rheumatoid arthritis (RA) in combination with pharmacological anti-arthritic medications.

Methods: Forty-five adult men and women with symptoms of RA were randomly assigned to receive Bacillus coagulans GBI-30, 6086 or placebo once a day in a double-blind fashion for 60 days in addition to their standard anti-arthritic medications. Arthritis activity was evaluated by clinical examination, the American College of Rheumatology (ACR) criteria, the Stanford Health Assessment Questionnaire Disability Index (HAQ-DI), and laboratory tests for erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).

Results: Subjects who received Bacillus coagulans GBI-30, 6086 experienced borderline statistically significant improvement in the Patient Pain Assessment score (P = .052) and statistically significant improvement in Pain Scale (P = .046) vs placebo. Compared with placebo, Bacillus coagulans GBI-30, 6086 treatment resulted in greater improvement in patient global assessment and self-assessed disability; reduction in CRP; as well as the ability to walk 2 miles, reach, and participate in daily activities. There were no treatment-related adverse events reported throughout this study.

Conclusions: Results of this pilot study suggest that adjunctive treatment with Bacillus coagulans GBI-30, 6086 LAB probiotic appeared to be a safe and effective for patients suffering from RA. Because of the low study population size, larger trials are needed to verify these results.

Trial registration: ACTRN12609000435280.

Figures

Figure 1
Figure 1
Study flowchart.

References

    1. Gill H, Prasad J. Probiotics, immunomodulation, and health benefits. Adv Exp Med Biol. 2008;606:423–454. full_text.
    1. Goldin BR, Gorback SL. Clinical indications for probiotics: an overview. Clin Infect Dis. 2008;46(suppl 2):S96–S100. doi: 10.1086/523333.
    1. Baharav E, Mor F, Halpern M, Weinberger A. Lactobacillus GG bacteria ameliorate arthritis in Lewis rats. J Nutr. 2004;134:1964–1969.
    1. Sheil B, McCarthy J, O'Mahony L, Bennett MW, Ryan P, Fitzgibbon JJ, Kiely B, Collins JK, Shanahan F. Is the mucosal route of administration esential for probiotic function? Subcutaneous administration is associated wtih attenuation of murine colitis and arthritis. Gut. 2004;53:694–700. doi: 10.1136/gut.2003.027789.
    1. Hatakka K, Martio J, Korpela M, Herranen M, Poussa T, Laasanen T, Saxelin M, Vapaatalo H, Moilanen E, Korpela R. Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis-a pilot study. Scand J Rheumatol. 2003;32:211–215. doi: 10.1080/03009740310003695.
    1. Schultz M, Linde HJ, Lehn N, Zimmerman K, Grossmann J, Falk W, Shölmerich J. Immunomodulatory consequences of oral administration of Lactobacillus rhamnosus strain GG in healthy volunteers. J Dairy Res. 2003;70:165–173. doi: 10.1017/S0022029903006034.
    1. Vaarala O. Immunlogical effects of probiotics with speical reference to lactobacilli. Clin Exp Allergy. 2003;33:1634–1640. doi: 10.1111/j.1365-2222.2003.01835.x.
    1. Sheih YH, Chiang BL, Wang LH, Liao CK, Gill HS. Systemic immunity-enhancing effects in health subject following dietary consumption of the lactic acide bacterium Lactobacillus rhamnosus HN001. J Am Coll Nutr. 2001;20(2 suppl):149–156.
    1. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh K, Liang MH, Dremers HM, Mayes MD, Merkel PA, Pillemer SR, Rveille JD, Stone JH. for the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum. 2008;58:15–25. doi: 10.1002/art.23177.
    1. Sesin CA, Bingham CO. Remission in rheumatoid arthritis: wishful thinking for clinical reality? Semin Arthritis Rheum. 2005;35:185–196. doi: 10.1016/j.semarthrit.2005.06.003.
    1. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov. 2003;2:473–488. doi: 10.1038/nrd1109.
    1. Arend WP. Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Care Res. 2001;45:101–106. doi: 10.1002/1529-0131(200102)45:1<101::AID-ANR90>;2-7.
    1. Sartor RB. Review article: Role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis. Aliment Pharmacol Ther. 1997;11(suppl 3):17–22.
    1. Malin M, Verronen P, Korhonen H, Syväoja EL, Salminen S, Mykkänen H, Arvilommi H, Eerola E, Isolauri E. Dietary therapy with Lactobacillus GG, bovine colostrum or bovine immune colostrum in patients with juvenile chronic arthritis: Evaluation of effect on gut defence mechanisms. Inflammopharmacology. 1997;5:219–236. doi: 10.1007/s10787-997-0001-1.
    1. So JS, Kwon HK, Lee CG, Yi HJ, Park JA, Lim SY, Hwang KC, Jeon YH, Im SH. Lactobacillus casei suppresses experimental arthritis by down-regulating T helper 1 effector functions. Mol Immunol. 2008;45:690–699. doi: 10.1016/j.molimm.2007.07.006.
    1. Rodriguez-Cabezas ME, Fisac F, Bailon E, Comalada M, Camuesco D, Xaus J, Concha A, Talavera P, Nieto A, Zarzuelo A, Galvez J. Lactobacillus fermentum exerts a beneficial effect in an experimental model of rheumatoid arthritis in mice. Proc Nutr Soc. 2008;67:E66. doi: 10.1017/S0029665108006757.
    1. Kano H, Kaneko T, Kaminogawa S. Oral intake of Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 prevents collagen-induced arthritis in mice. J Food Prot. 2002;65:153–160.
    1. Kato I, Endo-Tanaka K, Yokokura T. Suppressive effects of the oral administration of Lactobacillus casei on type II collagen-induced arthritis in DBA/1 mice. Life Sci. 1998;63:635–644. doi: 10.1016/S0024-3205(98)00315-4.
    1. Broek MF van den, van Bruggen MC, Kiipman JP, Hazenberg MP, Berg WB van den. Gut flora induces and maintains resistance against streptococcal cell wall-induced arthritis in F344 rates. Clin Exp Immunol. 1992;88:313–317.
    1. Casula G, Cutting SM. Bacillus probiotics: spore germination in the gastrointestinal tract. Appl Environ Microbiol. 2002;68:2344–2352. doi: 10.1128/AEM.68.5.2344-2352.2002.
    1. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R, Paulus H, Strand V, Tugwell P, Weinblatt M, Williams HJ, Wolfe F, Kieszak S. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727–735. doi: 10.1002/art.1780380602.
    1. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ) Clin Exp Rheumatol. 2005;23:S14–S18.
    1. Tlaskalová-Hogenová H, Štĕpánková R, Hudcovic T, Tucková L, Cukrowska B, Lodinová-Žádníková R, Kozáková H, Rossmann P, Bárová J, Sokol D, Funda DP, Borovská D, Řeháková Z, Šinkora J, Hofman J, Drastich P, Kokešová A. Commendal bacterial (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett. 2004;93:97–108. doi: 10.1016/j.imlet.2004.02.005.
    1. De Vecchi E, Drag L. Lactobacillus sporogenes or Bacillus coagulans: misidentification or mislabeling? Int J Probiotics Prebiotics. 2006;1:3–10.
    1. Tuomola E, Crittenden R, Playne M, Isolauri E, Salminen S. Quality assurance criteria for probiotic bacteria. Am J Clin Nutr. 2001;73(suppl):393S–398S.
    1. Marco ML, Pavan S, Kleerebezem M. Towards understanding molecular modes of probiotic action. Curr Opin Biotechnol. 2006;17:204–210.
    1. Hyronimus B, Le Marrec C, Sassi AH, Deschamps A. Acid and bile tolerance of spore-forming lactic acid bacteria. Int J Food Microbiol. 2000;61:193–197. doi: 10.1016/S0168-1605(00)00366-4.
    1. Hyronimus B, Le Marrec C, Urdaci MC. Coagulin, a bacteriocin-like inhibitory substance produced by Bacillus coagulans I4. J Appl Microbiol. 1998;85:42–50. doi: 10.1046/j.1365-2672.1998.00466.x.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner